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Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib
is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related
case of ophthalmologic toxicity has been reported with another vascular endothelial growth
factor receptor inhibitor, sunitinib.We report the first case of retinal tear possibly associated
with sorafenib.
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INTRODUCTION
Sorafenib is on oral inhibitor of multiple tyrosine kinases,
including vascular endothelial growth factor receptors (VEGFR),
approved for the treatment of unresectable hepatocellular carci-
noma (HCC) and advanced renal cell carcinoma (1). The most
common adverse events noted with sorafenib include hand–foot
syndrome, rash, diarrhea, fatigue, and hypertension (2). We report
the first case of retinal tear possibly associated with sorafenib.
BACKGROUND
A 66-year-old Caucasian male with past medical history remark-
able for hypertension was diagnosed with HCC in the setting of
non-alcoholic fatty liver disease and cirrhosis. The patient was
deemed not to be a candidate for surgical resection or liver trans-
plant given the presence of satellite lesions. His HCC was treated
initially with transcatheter arterial chemoembolization (TACE).
Subsequently, two months later the patient was found to have dis-
ease progression described as multiple new liver lesions. Accord-
ingly, he was initiated on sorafenib 200 mg twice daily that was
titrated up by 200 mg weekly until he reached the goal dose of
400 mg twice daily. Three months after being on sorafenib 400 mg
twice daily the patient experienced multiple toxicities including
dry skin, palm sensitivity, fatigue, nausea, and persistent diarrhea.
Therefore, the dose was decreased to 200 mg twice daily, which
was better tolerated. After approximately eleven months on the
lower dose of 200 mg twice daily, the patient started to complain
of blurred vision in the right eye associated with seeing flashes
without pain or irritation. The patient’s ocular history was signif-
icant for mild myopia and hypertensive retinopathy in both eyes.
The patient’s vision was reported to be 20/30 in the right eye and
20/25 in the left eye. The patient’s right eye exam was remarkable
for posterior vitreous detachment and three retinal tears while
the left eye exam was unremarkable. The patient did not expe-
rience any trauma prior to his presentation. The sorafenib was
held for two weeks while the patient underwent laser retinopexy.
Sorafenib was subsequently resumed at 200 mg twice daily and
the patient continued to experience dry skin, fatigue, and palmar
sensitivity but no visual changes. Following these events, repeat
imaging indicated stability or regression of lesions except slight
enlargement of one, which was then treated with TACE. The dos-
ing of sorafenib remained appropriate or below the recommended
dose based on hepatic and renal function throughout the course
of therapy. No medication changes occurred during this time nor
were any drug interactions identified that may have resulted in
increased sorafenib exposure.
DISCUSSION
Many signaling molecules responsible for cancer growth, includ-
ing VEGF, are expressed in ocular tissues (3, 4). Increases in ocular
VEGF are associated with conditions such as proliferative diabetic
retinopathy and age-related macular degeneration, which may be
treated with intravitreal administration of VEGF inhibitors (3,
5). While the systemic use of VEGF inhibitors is associated with
minimal risk of ocular toxicity, there is a known risk of retinal
detachment with the use of local, intravitreal therapy (3, 4). In
addition, systemic VEGF inhibitors are associated with toxicities
that can lead to visual symptoms, such as systemic hypertension,
which may result in hypertensive retinopathy (3). We report the
first case of possible development of reversible retinal tears on
reduced dose sorafenib.
Retinal detachment affects 1 in 10,000 people per year (6).
The most common risk factors include aging, myopia, trauma,
cataract surgery, and focal retinal atrophy (6). With regards to
aging, approximately one in four in the seventh decade of life will
develop posterior vitreous detachment, with the incidence increas-
ing in the eighth decade (6). Age and mild myopia are the patient’s
only other known risk factors (6). In addition, it is unlikely that
the retinal tears in this case were due to hypertensive retinopathy
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since the patient’s blood pressure was stable throughout treatment
with sorafenib.
A similar case has been previously reported with the use of
sunitinib in a patient with renal cell carcinoma that was reversible
upon discontinuation of sunitinib (7). However, in the sunitinib
case the retinal detachment occurred significantly earlier, after
only 3 weeks of treatment (7). Sunitinib and sorafenib work by
inhibiting multiple intracellular signaling pathways involved in
cell proliferation and survival (8, 9). Neither agent purely inhibits
vascular targets. Sunitinib has been shown to inhibit VEGFR-1,
-2, and -3, platelet-derived growth factor receptors (PDGFR), and
c-KIT in vitro (10, 11). Sunitinib also produces an active metabo-
lite, SU012662, which has shown equal inhibitory activity toward
VEGFR, PDGFR, and c-KIT as sunitinib (10). Sorafenib inhibits
VEGFR-2 and -3, PDGFR, c-KIT, RAF-1, and BRAF, which results
in inhibition of VEGF receptors as well as downstream activity of
VEGF (12–14). Not only does sunitinib have activity at VEGF-1,
it also displays more potent inhibition of VEGFR-2 and -3 when
compared to sorafenib (8, 13). Reports of retinal complications
with systemic use of otherVEGFR inhibitors, such as bevacizumab,
have not been identified (15).
CONCLUDING REMARKS
This case highlights a potential risk of developing retinal tears
while on a systemic VEGFR inhibitor such as sorafenib. Though
additional work will be needed to determine causality, this report
is of great importance given the increased use of anti-angiogenesis
as treatment in a variety of malignancies. Whether the use of other
anti-angiogenesis inhibitors could lead to retinal tears remains to
be determined and should be reported accordingly. If a patient
on a systemic VEGF inhibitor develops visual symptoms, tempo-
rary discontinuation of therapy is advised until ophthalmological
evaluation can occur (3).
AUTHOR CONTRIBUTIONS
All authors contributed to the conception or design, draft or revi-
sion, final approval of the version to be published, and agree to be
accountable for all aspects of the work.
REFERENCES
1. Nexavar [Package Insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.
(2013).
2. Brose MS, Frenette CT, Keefe SM, Stain SM. Management of sorafenib-related
adverse events: a clinician’s perspective. Semin Oncol (2014) 41(2):S1–16.
doi:10.1053/j.seminoncol.2014.01.001
3. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxic-
ity of targeted therapies. J Clin Oncol (2012) 30(26):3277–86. doi:10.1200/JCO.
2011.41.5851
4. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for
ocular neovascular disease. Curr Opin Ophthalmol (2007) 18:502–8. doi:10.
1097/ICU.0b013e3282f0ca54
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat
Med (2003) 9(6):669–76. doi:10.1038/nm0603-669
6. Gariano RF, Kim CH. Evaluation and management of suspected retinal detach-
ment. Am Fam Physician (2004) 69(7):1691–8.
7. Wegner A, Khoramnia R. Neurosensory retinal detachment due to sunitinib
treatment. Eye (2011) 25:1517–8. doi:10.1038/eye.2011.200
8. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine
kinase inhibitors of vascular endothelial growth factor receptors in clini-
cal trials: current status and future directions. Oncologist (2006) 11:753–64.
doi:10.1634/theoncologist.11-7-753
9. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor path-
way in tumor growth and angiogenesis. J Clin Oncol (2005) 23(5):1011–27.
doi:10.1200/JCO.2005.06.081
10. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, phar-
macokinetic, and antitumor activity of SU11248, a novel oral multitarget tyro-
sine kinase inhibitor, in patients with cancer. J Clin Oncol (2006) 24(1):25–35.
doi:10.1200/JCO.2005.02.2194
11. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in
tumor progression. Crit Rev Oncol Hematol (2007) 62:179–213. doi:10.1016/
j.critrevonc.2007.01.006
12. Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of
metastatic renal cell carcinoma. Am J Health Syst Pharm (2008) 65(15):123–31.
doi:10.2146/ajhp060661
13. Bhargava P, Robinson MO. Development of second-generation VEGFR tyro-
sine kinase inhibitors: current status. Curr Oncol Rep (2011) 13:103–11.
doi:10.1007/s11912-011-0154-3
14. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets the
RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor pro-
gression and angiogenesis. Cancer Res (2004) 64:7099–109. doi:10.1158/0008-
5472.CAN-04-1443
15. Avastin [Package Insert]. South San Francisco, CA: Genentech, Inc. (2013).
Conflict of Interest Statement: Osama E. Rahma is a consultant on the advisory
board of Bayer. Kelly M. Gaertner and Stephen H. Caldwell have nothing to disclose.
Received: 25 June 2014; accepted: 10 July 2014; published online: 24 July 2014.
Citation: Gaertner KM, Caldwell SH and Rahma OE (2014) A case of retinal tear
associated with use of sorafenib. Front. Oncol. 4:196. doi: 10.3389/fonc.2014.00196
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the
journal Frontiers in Oncology.
Copyright © 2014 Gaertner, Caldwell and Rahma. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs July 2014 | Volume 4 | Article 196 | 2
